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Summary of clinical trial results: E4599 & AVAiL
In AVF0757g randomized phase II trial,1 patients with chemotherapy-naïve,
locally advanced, or metastatic non-small cell lung cancer (NSCLC) were
randomized to receive six cycles of carboplatin (AUC 6) and paclitaxel (200 mg/m2)
with or without bevacizumab 7.5 mg/kg or 15 mg/kg every 3 weeks until disease
progression. Patients in high-dose bevacizumab arm reported higher response
rates (RR), longer time to progression (TTP), and overall survival (OS) compared
with those receiving chemotherapy alone. In this study, squamous histology was
identified as a risk factor for life-threatening pulmonary hemorrhage. Thus, the
majority of subsequent trials of bevacizumab in NSCLC have excluded patients
with predominantly squamous cell histology.
Following the phase II trial that established the safety and efficacy of bevaci-
zumab in NSCLC, two pivotal phase III trials of carboplatin/paclitaxel with or
without bevacizumab (15 mg/kg; E4599) and of cisplatin/gemcitabine with or
without bevacizumab (7.5 mg/kg or 15 mg/kg; AVAiL) proved efficacy of
bevacizumab in patients with previously untreated advanced non-squamous
NSCLC.2,3 Based on positive data from these trials, bevacizumab was approved
by the U.S. Food and Drug Administration (FDA) and the European Medicines
Agency (EMEA). 
In the phase III Eastern Cooperative Oncology Group 4599 (E4599) study,2 878
patients were randomized to receive chemotherapy with paclitaxel/carboplatin
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BEVACIZUMAB
chemotherapy alone (PC arm) or chemotherapy plus
bevacizumab 15 mg/kg (PCB arm). Patients with squamous
cell tumors, brain metastases and clinically significant
hemoptysis were excluded. Patients receiving bevacizumab
had a significantly higher RR (35% versus 15%; p <
0.001), median progression-free survival (PFS) [6.2 versus
4.5 months; hazard ratio (HR), 0.66; p < 0.001], and also
median OS (12.3 versus 10.3 months; HR, 0.79; p = 0.003).
Although a consistent effect was observed across most
subgroups, in an exploratory analysis, evidence of survival
benefit was not observed in women (HR 0.98, 95% CI
0.77-1.25). The reason for this is unclear, but it may be
explained by the fact that more women were receiving
second-line chemotherapy in the PC arm, although there
was no difference in the subsequent use of epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitors
(EGFR-TKIs). There might also be imbalances between
the two groups with respect to known or unknown progno-
stic factors; there was a higher incidence of liver metastases
in women receiving bevacizumab. Given that smoking
history is a predictive factor for the efficacy of EGFR
inhibitors,4 the lack of this important data in this study
complicated the interpretation of the potential impact of
subsequent EGFR-TKIs on the clinical outcome. Additio-
nally, because female patients with advanced NSCLC
showed significantly longer survival, regardless of any
treatment, they might derive little additional benefit, if any,
from a bevacizumab-containing regimen. 
In a second large phase III trial (AVAiL),3 comparing
cisplatin/gemcitabine (CG) alone versus CG in combination
with bevacizumab (7.5 or 15 mg/kg) and PFS, the primary
end point of the study was significantly longer in both
bevacizumab treatment arms compared with the placebo
arm. The HR for PFS was 0.75 (p = 0.003) for the low-dose
bevacizumab arm versus placebo (median PFS, 6.7 versus
6.1 months, respectively) and 0.82 (p = 0.03) for the high-
dose bevacizumab arm versus placebo (median PFS, 6.5
versus 6.1 months, respectively). Furthermore, the objective
RR and median duration of response were significantly
higher in both bevacizumab arms compared with the
placebo arm (30% versus 34% versus 20% in 15 mg/kg,
7.5 mg/kg and placebo arms, respectively). Although the
trial was not powered to directly compare the two bevaci-
zumab doses, the results indicate similar efficacy in terms
of PFS and RR for low- and high-dose bevacizumab arm.
However, in a final OS analysis with median 12.5 months
follow-up, AVAiL did not demonstrate a significant OS
benefit, a secondary endpoint, in the bevacizumab arm
(median OS, 13.4 versus 13.6 versus 13.1 months in 15
mg/kg, 7.5 mg/kg and placebo arms, respectively).6
Potential explanations for the discrepancy of OS benefit
between E4599 and AVAiL may exist. Firstly, this simply
indicate that second-line therapies may potentially impact
study outcomes. It is critical to recognize that approximately
60% of patients in the AVAiL trial have received subse-
quent lines of therapy, with approximately 40% of these
patients receiving EGFR-TKIs. Interestingly, in an explo-
ratory analysis of the group who did not receive post-
protocol therapies, patients receiving bevacizumab showed
trend towards better OS (8.7 versus 7.3 months in placebo
arm; HR, 0.84; p = 0.20).6 Secondly, the remarkably long
median OS in control arm (13.1 months) in AVAiL trial
might necessitate larger sample size in order to demon-
strate statistically significant OS benefit. Thirdly, bevaci-
zumab may be more effective with paclitaxel/carboplatin
regimen than with gemcitabine/cisplatin regimen. Never-
theless, failure to demonstrate OS benefit in AVAiL, which
findings clearly contrast with those of E4599, call into
question the magnitude of benefits patients will gain from
the addition of bevacizumab to standard chemotherapy.
In conclusion, bevacizumab added to palliative chemo-
therapy has improved PFS in two phase III trials and OS in
one of these trials in selected patients with advanced
NSCLC. Based on these results, bevacizumab has now
been  approved in the first-line treatment of nonsquamous
NSCLC in many countries. 
Safety and toxicity results
In E4599 trial, the rate of hypertension, proteinuria, bleeding,
neutropenia, febrile neutropenia, thrombocytopenia, hypo-
natremia, rash, and headache were significantly higher in
the bevacizumab arm than in the control arm.2 There was
significantly higher incidence of treatment-related toxic
deaths in bevacizumab arm compared with the control arm
(4.6% versus 0.5%, p = 0.001). The most serious, and
sometimes fatal, adverse events (AEs) in patients receiving
bevacizumab were pulmonary hemorrhage, gastrointes-
tinal (GI) hemorrhage or perforation, neutropenic sepsis,
and arterial-venous thrombosis (cerebrovascular event or
pulmonary embolism). The bleeding events (grade ≥ 3),
mainly represented by pulmonary hemorrhage, GI bleeding,
central nervous system hemorrhage and epistaxis, were
4.4% in the bevacizumab arm versus 0.7% in the control
arm (p < 0.001). In 1.9% of patients, these events were
fatal versus 0.2% in the control arm. 
In the AVAiL trial, the overall incidence of ≥ grade 3
AEs were similar across all arms.3 The incidence of serious
AEs did not differ between the placebo arm and the low-
dose bevacizumab arm (35% in each arm), but were higher
with the high-dose bevacizumab arm (44%). The rate of ≥
grade 3 hypertension, vomiting, neutropenia, bleeding, and
proteinuria were modestly higher in the bevacizumab arms
than in the placebo arm. Severe pulmonary hemorrhage
was increased in the bevacizumab arms (1.5% in low-dose
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bevacizumab arm versus 0.9% in high-dose bevacizumab
arm versus 0.6% in placebo arm) and included 7 fatal events
(2.1%). There was no observed increase in the incidence of
arterial or venous thrombosis or GI perforation. 
Bevacizumab use in high-risk group of developing 
hemorrhage: is the risk real?
The risk of a pulmonary hemorrhage with bevacizumab is
of concerning toxicity, and investigation of risk factors for
developing this toxicity is essential. In a pooled analysis of
1,142 bevacizumab-treated patients across three bevaci-
zumab trials (AVF0757g, E4599 and AVAiL), only 21
cases (1.8%) of severe pulmonary hemorrhages were
reported.1-3 There was no evidence for an association
between any baseline clinical variables (prior radiotherapy/
surgery, age, gender, ECOG performance status) and the
incidence of early-onset pulmonary hemorrhages.8 Baseline
tumour cavitation may be a potential risk factor for severe
pulmonary hemorrhage. Central location, tumor size,
vascular involvement, and tracheobronchial involvement
was not associated with a higher risk of a severe pulmonary
hemorrhage. Overall, pulmonary hemorrhage associated
with bevacizumab-based regimen could be considered an
uncommon event in a selected patients with nonsquamous
NSCLC. 
In the AVF0757g study, the incidence of severe or fatal
pulmonary hemorrhage was 31% in patients with squamous
histology and 4% in patients with histology other than
squamous cell carcinoma, suggesting that squamous cell
histology may be one of the possible risk factors for the
development of a severe pulmonary hemorrhage.1 However,
because squamous cell carcinoma is more likely to be
centrally located and have a greater tendency to cavitate, it
is not clear if histology is the central risk factor for bleeding
or simply a surrogate marker for other risk factors.8 More-
over, patients with the central nervous system (CNS)
metastasis have been excluded from bevacizumab trials
based on the occurrence of fatal hemorrhages in hepatoma
patients with brain metastasis in the earlier phase I study.9
However, the risk of serious CNS hemorrhage for patients
with CNS metastasis has not been formally evaluated.
Therefore, one may ask whether bevacizumab is safe in
patients with predominantly squamous NSCLC or whether
bevacizumab increases the risk of CNS bleeding in patients
who have CNS metastasis or who develop CNS metastasis
during the course of therapy. Additional investigation of
potential risk factors and strategies to reduce the severe
hemorrhage should be warranted to safely expand the
eligibility for bevacizumab-based therapy in these patients
with advanced NSCLC. 
To this end, the AVASQ and Bridge phase II trials are
focused on patients with squamous NSCLC, whereas the
PASSPORT trial is enrolling patients with treated CNS
metastases. Preliminary data from PASSPORT and other
study suggest the safety of bevacizumab in advanced
NSCLC patients with treated CNS metastasis.10 Further-
more, a retrospective analysis of E4599 and AVAiL study
showed that bevacizumab did not appear to increase the
risk of CNS hemorrhages in patients with documented
CNS progression.11 Preliminary analysis in over 1,000
patients enrolled in a Safety of Avastin in Lung (SAiL)
study assessing the safety of bevacizumab combined with
standard chemotherapy regimens also suggests safety of
bevacizumab in patients with CNS metastasis during the
course of therapy.12 
There may be some valid concern about the effect of
concomitant cardiovascular or anticoagulation medication
on bevacizumab-based therapy. Preliminary reports from
the SAiL study suggest that bevacizumab could be safely
administered in advanced NSCLC patients receiving
concomitant antihypertensive or anticoagulation medi-
cation.13 Furthermore, in the AVAiL study, nine percent of
the study population received therapeutic anticoagulation
after the baseline, and no pulmonary hemorrhage was
observed in these patients.3
Role of bevacizumab maintenance 
It is unclear whether maintenance treatment beyond the
completion of 4 to 6 cycles of chemotherapy offers an
additional survival advantage. There is indirect evidence
supporting the use of bevacizumab until disease pro-
gression. In a preclinical study, Vosseler, et al.14 showed
that early withdrawal of anti-vascular endothelial growth
factor (VEGF) therapy resulted in rapid vessel regrowth. In
an AVF0757g study, 19 of the 32 control patients crossed
over to single agent bevacizumab on disease progression
and five experienced disease stabilizations for more than 6
months.1 Furthermore, the potential beneficial effect of
bevacizumab maintenance may have impacted the im-
pressive median survival (14.9 months) of the control
group in this study. Other clinical support for continued
VEGF inhibition came from phase III trials of metastatic
colorectal cancer, demonstrating significant increases in
PFS, regardless of tumour response, through the addition
of bevacizumab to chemotherapy.15 Given that over 90%
of patients eligible for bevacizumab monotherapy received
maintenance bevacizumab in the AVAiL study3 and severe
adverse events were rare in 215 patients receiving beva-
cizumab monotherapy in the E4599 study,2 maintenance
therapy with bevacizumab could be considered feasible
and safe. Because the true value of maintenance beva-
cizumab can be determined only in the future phase III
trial, it should be used, for the present, in all eligible
patients. 
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Bevacizumab use in elderly population 
In an exploratory analysis of E4599, elderly patients (age ≥
70 years)  experienced more toxicity with PCB compared
with younger patients.16 At least one episode of grade 3 or
worse toxicity was noted in 87% of the elderly patients,
compared with 70% of the younger patients on the PCB
arm (p < 0.001). Furthermore, among the 15 treatment-
related deaths recorded in the PCB arm, the incidence in
the elderly was 6.3% compared with 2.6% in the younger
cohort. In terms of efficacy, there were trends toward
superior RRs (28.7% versus 17.3 with PC; p = 0.067) and
PFS (median PFS, 5.9 months versus 4.9 months with PC;
p = 0.063) with PCB for elderly patients. However, there
was no significant difference in OS between PCB and PC
(11.3 versus 12.1 with PC; p = 0.4). In elderly NSCLC
patients, bevacizumab-based therapy was associated with a
higher degree of toxicity, but no obvious improvement in
survival compared with chemotherapy alone. The increased
toxicity observed in elderly may have contributed to the
absence of a survival benefit in the bevacizumab arm.
Subgroup analysis of the AVAiL study to evaluate the
outcome for elderly could provide additional information
regarding the safety of bevacizumab-based therapy in
these patients. 
To date, no prospective data of bevacizumab-based
regimen in elderly NSCLC patients are available. Therefore,
elderly-specific prospective studies are crucial to establish
the therapeutic index of bevacizumab-based therapy and,
more importantly, help ascertain the appropriate dose of
bevacizumab in those who are most vulnerable to the
toxicities of therapy.3
Role of bevacizumab in Asian population 
Based on two pivotal trials, could bevacizumab-based
therapy be considered a new standard of care for first-line
treatment of advanced NSCLC in Asian populations? As a
matter of fact, most patients enrolled in the E4599 study
were Caucasians (only 1.9% of patients were of Asian
origin), preventing any exploratory analysis in the Asian
subgroup.2 Approximately 9% of patients enrolled in the
AVAiL study were East Asians, and there appeared to be
no difference in the beneficial effects of bevacizumab on
PFS by ethnicity in the subgroup analysis.3 Recently, small
randomized phase II study of carboplatin and paclitaxel
with or without bevacizumab in chemotherapy-naïve
Japanese patients with advanced nonsquamous NSCLC
(JO19907) showed the addition of bevacizumab to chemo-
therapy significantly improved PFS and RR.17 The HR of
PFS (HR, 0.55; p = 0.0028) seemed at least as good as
previous trials of E4599 and AVAiL. 
Several points should be addressed. Because it is well
known that EGFR TKIs are more effective in Asian pati-
ents,4 the potential survival impact of second-line therapy
may be an important confounding factor that influences
overall survival after disease progression on bevacizumab-
based first-line therapy. Additionally, because median
survival of Asians with advanced NSCLC was better than
that of Western population, it might be more difficult to
detect small, but potentially relevant, benefits from bevaci-
zumab in Asians. However, since the predictive role of
ethnicity for antiangiogesis therapy, in contrast to EGFR
inhibitors, is not yet proven, a similar degree of survival
benefits might be anticipated from bevacizumab-based
first-line therapy in Asian populations. 
Predictive biomarker for benefit from bevacizumab 
combination
In a biomarker analysis of E4599 study, patients with high
VEGF levels were more likely to have an increased
probability of response with the addition of bevacizumab
(RR, 33% on PCB arm versus 7.7% on PC arm, p = 0.01)
than those with low VEGF levels (RR, 28.6% on PCB arm
versus 29% on PC arm, p = not significant), but this was
not predictive of survival.18 On the other hand, patients with
low baseline ICAM had a higher response rate (32%
versus 14%; p = 0.02), better overall survival (p = 0.00005),
and better 1-year survival (65% versus 25%) than those
with high ICAM, respectively, regardless of treatment arm. 
When comparing PFS between the high-dose bevaci-
zumab and placebo group in biomarker analysis of AVAiL
study, there was a trend towards a larger treatment effect in
patients with low ICAM-1 levels compared to patients
with high ICAM-1 levels.19 Comparing OS between the
low-dose bevacizumab and placebo arms, a larger treat-
ment effect was observed in patients with high bFGF
levels compared to low bFGF levels.
Summary of clinical trial results
The potential survival advantage by adding cetuximab to
standard chemotherapy was first suggested in a rando-
mized phase II trial-the Lung Cancer Cetuximab Study
(LUCAS).20 In this trial, cisplatin/vinorelbine plus cetuximab
was compared with chemotherapy alone in 86 patients
with EGFR-positive NSCLC. The addition of cetuximab
improved the RR (35% vs. 28%), PFS (5.0 vs. 4.6 months),
and OS (8.3 vs. 7.3 months), respectively. Skin toxicity was
the most common cetuximab-related adverse event (10%
grade 3 or 4). In a Canadian randomized phase II trial,
Butts, et al.21 reported a trend toward improved PFS and OS
for cetuximab in combination with platinum and gemci-
tabine compared with chemotherapy alone. On the other
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CETUXIMAB 
hand, BMS099 phase III trial testing cetuximab in com-
bination with taxanes (either paclitaxel or docetaxel) and
carboplatin in patients (n = 676; not screened for EGFR
expression in tumor) with advanced NSCLC failed to
show clear-cut advantages in PFS by the Independent
Radiology Review Committee, the primary endpoint of the
study, compared with chemotherapy alone.22 However,
several secondary efficacy endpoints, such as RR and PFS
(based on investigator’s assessment), favored the cetuximab
combination. Additionally, mature survival results from
this trial suggest a potential benefit from the addition of
cetuximab with a median survival of 9.7 months vs. 8.4
months for the control arm, although it did not reach statis-
tical significance (HR, 0.89, 95% CI, 0.754-1.051; p = 0.17).
Overall, three phase II and one phase III trials clearly sug-
gested potential survival benefits with predictable and mana-
geable toxicity profiles in cetuximab-containing regimen. 
Encouraging findings from the previous studies have
been confirmed prospectively in a larger phase III trial- the
First-Line in Lung Cancer with Erbitux (FLEX).23 In this
trial, patients stratified according to ECOG performance
status (0-1 vs. 2) and disease stage (stage IIIB vs. IV) were
randomized 1 : 1 to receive either cetuximab (400 mg/m2
initial dose then 250 mg/m2 weekly), cisplatin 80 mg/m2 on
day 1 and vinorelbine 25 (30) mg/m2 on days 1 and 8 of a 3-
week cycle or chemotherapy alone. After up to 6 treatment
cycles, patients in the cetuximab arm could continue weekly
cetuximab monotherapy until disease progression or
unacceptable toxicity. Contrary to the E4599 and AVAiL
studies, patients with squamous carcinoma and borderline
performance status (PS; e.g., PS2) could be eligible. Based
on the postulated action mechanism of cetuximab, eligible
patients were required to show EGFR expression in tumors
detected by immunohistochemistry (IHC). The median
OS, the primary endpoint, was significantly prolonged in
patients treated with cetuximab in combination with che-
motherapy (11.3 months) compared with chemotherapy
alone (10.1 months) (HR 0.871, 95% CI 0.762-0.996; p =
0.044). Regarding the secondary endpoints, RR was
significantly better in the cetuximab arm (36% vs. 29%, p
= 0.012), whereas the median PFS was 4.8 months in both
arms. Pre-specified subgroup analysis showed the survival
benefit, regardless of histology, ECOG PS, gender, and
age. This observation clearly contrasts with the results of
bevacizumab, and potentially establishes cetuximab in
combination with chemotherapy as a standard option in
bevacizumab-ineligible patients, particularly those with
squamous histology or PS2. Furthermore, given that the
bevacizumab combination did not improve survival in
elderly patients, the cetuximab combination might be a
more reasonable option to choose in this frail population. 
A recent meta-analysis of phase II/III trials based on
2,018 individual patient data demonstrated a significant
benefit of adding cetuximab to first-line chemotherapy in
terms of OS (HR, 0.878; p = 0.010), PFS (HR, 0.899; p =
0.036) and RR (odds ratio, 1.463; p < 0.001), respectively,
over chemotherapy alone.24
Impact of FLEX in Asian population
The results of FLEX are also remarkable in highlighting a
discordance in outcome between white and Asian patients.25
Asian populations, accounting for approximately 10% of
patients (n = 121) in this trial, showed a median survival
nearly double that observed in white populations. However,
cetuximab offered no additional benefit to Asian popula-
tions. In fact, patients receiving chemotherapy alone appe-
ared to be slightly better, with a median survival of 20.4
months compared with 17.6 months for receiving cetuximab
combination. It should be noted, however, that potential
bias might explain this observation: the proportion of
adenocarcinoma, which is a well-known predictor of
EGFR TKI response, was significantly higher in the
control arm than in the cetuximab arm (80% versus 65%).
Moreover, more patients in the control arm received EGFR
TKI post-study, compared with those in the cetuximab arm
(73% versus 50%). These factors might obscure survival
benefit from first-line cetuximab among Asian populations.
Because of the potential biases and the lack of adequate
power, the subset analysis cannot be inappropriately used
to deny the benefit of cetuximab in Asian populations.
Among Caucasian populations (n = 946), the survival
benefit from adding cetuximab appeared more prominent,
with a median survival of 10.5 months compared with 9.1
months for the control arm (HR, 0.80; p = 0.003). Given the
latest interest in histology, patients with adenocarcinoma
demonstrated a 1.7 months survival benefit from cetuxi-
mab (12.0 versus 10.3 months; HR, 0.81). A significant
survival benefit was also seen in patients with squamous
cell carcinoma (10.2 versus 8.9 months; HR, 0.79). 
Safety and toxicity results
The principal cetuximab-related adverse events in FLEX
study were acne-like rash (only grade 3, 10%), diarrhea
(5%), and infusion reactions (4%), respectively.23 These
toxicities typical of EGFR inhibitors were predictable and
manageable. The incidence of febrile neutropenia was
significantly higher in the cetuximab arm, compared with
in control arm (22% vs. 15%, p < 0.05). However, other pre-
vious studies evaluating cetuximab in combination with
platinum-based chemotherapy have shown considerably
lower rates of febrile neutropenia.21,22 Furthermore, febrile
neutropenia in the cetuximab arm neither increased the
incidence of sepsis or treatment-related deaths nor inter-
fered with drug delivery. However, high incidences of
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febrile neutropenia and grade 4 neutropenia in the cetuxi-
mab arm in the FLEX and LUCAS trials warrants special
attention, especially when combining cetuximab with
cisplatin/vinorelbine.20,23
Predictive biomarkers for benefits from cetuximab 
combination
Is a 1.2 months improvement in median OS worth it, albeit
high cost? As was discussed at the American Society of
Clinical Oncolgy in 2008, the median survival benefit to
2.5 months is essential for cetuximab-based therapy to be
cost-effective. Therefore, selecting patients who might
truly benefit from cetuximab is one of the most important
research questions that needs to be addressed. The predic-
tive value of EGFR protein expression for cetuximab-
treatment still remains controversial. For example, some
studies in metastatic colorectal cancer have suggested that
cetuximab showed activity in patients without EGFR
expression as determined by IHC.26,27 Given that 85% of
patients screened showed EGFR positivity, it may be true
that there was little, if any, patient selection based on
biomarkers in the FLEX study.23 In this virtually ‘unselected’
population, it may be inevitable that overall clinical benefit
from the addition of cetuximab is only modest. However,
it is also conceivable that exclusion of EGFR-negative
patients might have eliminated the pool of patients who
were least likely to benefit. Therefore, until the discovery
of an alternative biomarker for cetuximab, confirmation of
EGFR expression by IHC may be required for the use of
cetuximab in advanced NSCLC. 
Then, what are the leading candidates as predictors of
cetuximab efficacy? Recently, Hirsch, et al.28 reported that
EGFR gene copy numbers detected by fluorescent in situ
hybridization (FISH) were associated with better outcomes
in non-small-cell lung cancer (NSCLC) patients receiving
chemotherapy with cetuximab in a randomized phase II
trial (S0342). Among various biomarkers other than EGFR,
KRAS mutation has received the most attention. Many
studies have consistently shown that KRAS mutation pre-
dicts cetuximab resistance in colorectal cancer.29,30 Devel-
opment of skin rash during treatment might also be a
potential predictor for significant benefit from cetuximab-
based therapy, as was the case for various cancer types.31
In a recent biomarker analysis of FLEX study, skin rash
of any grade during the first cycle, but not EGFR or KRAS
mutation status, was associated with significantly better
survival (median OS, 15.0 versus 8.8 months in patients
who did not develop first cycle rash; HR= 0.63, p < 0.001).32
In conclusion, cetuximab is the first EGFR-targeted
agent to demonstrate a survival benefit in combination
with chemotherapy in the first-line treatment of advanced
NSCLC regardless of histology, KRAS mutation status,
and EGFR gene copy number. Results from FLEX and
earlier studies strongly suggest that cetuximab in combina-
tion with platinum-based chemotherapy improves survival
in patients with advanced EGFR-expressing NSCLC.
After a series of failures to demonstrate survival benefits of
targeted agents plus chemotherapy in 15 randomized phase
III trials with over 12,000 patients accrued, we eventually
took a step forward in the first-line treatment of advanced
NSCLC. Both bevacizumab and cetuximab are also likely
to work in Asian patients with advanced NSCLC. Two
strategies of targeting VEGF with bevacizumab or EGFR
with cetuximab are complementary to improve the survival
of a broad population of patients with advanced NSCLC,
and hopefully open new opportunities in the treatment of
those stricken with this debilitating disease in the near
future. No data to support selecting patients for bevaci-
zumab or cetuximab based-therapy on biomarker status are
currently available. Given the high cost and the modest
benefit with potentially serious toxicity from the addition
of either of these agents to standard chemotherapy, further
researches to identify biomarkers for predicting significant
benefits are urgently needed. 
1. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemu-
naitis JJ, Jablons DM, et al. Randomized phase II trial comparing
bevacizumab plus carboplatin and paclitaxel with carboplatin and
paclitaxel alone in previously untreated locally advanced or
metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:
2184-91.
2. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati
A, et al. Paclitaxel-carboplatin alone or with bevacizumab for
non-small-cell lung cancer. N Engl J Med 2006;355:2542-50.
3. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V,
Hirsh V, et al. Phase III trial of cisplatin plus gemcitabine with
either placebo or bevacizumab as first-line therapy for nonsqua-
mous non-small-cell lung cancer: AVAil. J Clin Oncol 2009;27:
1227-34.
4. Jänne PA, Engelman JA, Johnson BE. Epidermal growth factor
receptor mutations in non-small cell lung cancer: implications for
treatment and tumor biology. J Clin Oncol 2005;23:3227-34.
5. Dowlati A, Gray R, Sandler AB, Schiller JH, Johnson DH. Cell
adhesion molecules, vascular endothelial growth factor, and basic
fibroblast growth factor in patients with non-small cell lung
cancer treated with chemotherapy with or without bevacizumab--
an Eastern Cooperative Oncology Group Study. Clin Cancer Res
2008;14:1407-12. 
6. Manegold C, von Pawel J, Zatloukal P, Ramlau R, Gorbounova
V,  Hirsh V, et al. BO17704 (AVAiL): a phase III randomised study
Byoung Chul Cho, et al.
Yonsei Med J   http://www.eymj.org    Volume 51   Number 1   January 20106
CONCLUSION
REFERENCES
of first-line bevacizumab combined with cisplatin/gemcitabine in
patients  with advanced or recurrent non-squamous, non-small
cell lung cancer (NSCLC). Ann Oncol 2008;19:9S (abstr LBA1). 
7. Pirker R, Szczesna A, von Pawel J, Krzakowski M, Ramlau R,
Park K, et al. FLEX: a randomized, multicenter, phase III study
of cetuximab in combination with cisplatin/vinorelbine (CV)
versus CV alone in the first-line treatment of patients with
advanced non-small cell lung cancer (NSCLC). J Clin Oncol
2008;26 (May 20 Suppl; abstr 3).
8. Sandler AB, Schiller JH, Gray R, Dimery I, Brahmer J, Samant
M, et al. Retrospective evaluation of the clinical and radiographic
risk factors associated with severe pulmonary hemorrhage in
first-line advanced, unresectable non-small-cell lung cancer
treated with carboplatin and paclitaxel plus bevacizumab. J Clin
Oncol 2009;27:1405-12.
9. Gordon MS, Margolin K, Talpaz M, Sledge GW Jr, Holmgren E,
Benjamin R, et al. Phase I safety and pharmacokinetic study of
recombinant human anti-vascular endothelial growth factor in
patients with advanced cancer. J Clin Oncol 2001;19:843-50.
10. Akerley WL, Langer CJ, Oh Y, Strickland DK, Joo Royer S, Xia
Q, et al. Acceptable safety of bevacizumab therapy in patients
with brain metastases due to non-small cell lung cancer. J Clin
Oncol 2008;26 (May 20 Suppl; abstr 8043).
11. Archer V, Reck M, Sandler AB, Johnson DH, Kong G, Strickland
DK, et al. Risk of symptomatic central nervous system (CNS)
progression and secondary hemorrhage in patients with non-
squamous non-small cell lung cancer (NSCLC) receiving bevaci-
zumab (BV)-based first-line therapy. J Clin Oncol 2008;26 (May
20 Suppl; abstr 8114).
12. Dansin E, Mezger J, Isla D, Barlesi F, Bearz A, Garrido Lopez P,
et al. Safety of bevacizumab-based therapy as first-line treatment
of patients with advanced or recurrent non-squamous non-small
cell lung cancer (NSCLC): MO19390 (SAiL). J Clin Oncol 2008;
26 (May 20 Suppl; abstr 8085).
13. Griesinger F, Laskin JJ, Pavlakis N, on behalf of the MO19390
(SAiL) study group. Safety of first-line bevacizumab-based
therapy with concomitant cardiovascular or anticoagulation
medication in advanced or recurrent non-squamous non-small
cell lung cancer (NSCLC) in MO19390 (SAiL). J Clin Oncol
2008;26 (May 20 Suppl; abstr 8049).
14. Vosseler S, Mirancea N, Bohlen P, Mueller MM, Fusenig NE.
Angiogenesis inhibition by vascular endothelial growth factor
receptor-2 blockade reduces stromal matrix metalloproteinase
expression, normalizes stromal tissue, and reverts epithelial tumor
phenotype in surface heterotransplants. Cancer Res 2005;65:
1294-305.
15. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hains-
worth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil,
and leucovorin for metastatic colorectal cancer. N Engl J Med
2004;350:2335-42. 
16. Ramalingam SS, Dahlberg SE, Langer CJ, Gray R, Belani CP,
Brahmer JR, et al. Outcomes for elderly, advanced-stage non-
small-cell lung cancer patients treated with bevacizumab in
combination with carboplatin and paclitaxel: analysis of Eastern
Cooperative Oncology Group Trial 4599. J Clin Oncol 2008;26:
60-5.
17. Nishio M, Horai T, Kunitoh H, Ichinose Y, Nishiwaki Y, Hida T,
et al. Randomized, open-label, multicenter phase II sutdy of
bevacizumab in combination with carboplatin and paclitaxel in
chemotherapy-naive Japanese patients with advanced or recurrent
nonsquamous non-small cell lung cancer (NSCLC): JO19907. J
Clin Oncol 2009;27 (Suppl; abstr 8036).
18. Dowlati A, Gray R, Sandler AB, Schiller JH, Johnson DH. Cell
adhesion molecules, vascular endothelial growth factor, and basic
fibroblast growth factor in patients with non-small cell lung
cancer treated with chemotherapy with or without bevacizumab--
an Eastern Cooperative Oncology Group Study. Clin Cancer Res
2008;14:1407-12.
19. Leighl N, Reck M, de Haas S, Evers S, Delmar P, Manegold C, et
al. Analysis of biomarkers in the AVAiL phase III randomised
study of first-line bevacizumab with cisplatin-gemcitabine in
patients with non-small cell lung cancer. Eur J Cancer 2009;7
(abstr 9172).  
20. Rosell R, Robinet G, Szczesna A, Ramlau R, Constenla M,
Mennecier BC, et al. Randomized phase II study of cetuximab
plus cisplatin/vinorelbine compared with cisplatin/vinorelbine
alone as first-line therapy in EGFR-expressing advanced non-
small-cell lung cancer. Ann Oncol 2008;19:362-9.
21. Butts CA, Bodkin D, Middleman EL, Englund CW, Ellison D,
Alam Y, et al. Randomized phase II study of gemcitabine plus
cisplatin or carboplatin [corrected], with or without cetuximab, as
first-line therapy for patients with advanced or metastatic non
small-cell lung cancer. J Clin Oncol 2007;25:5777-84.
22. Lynch TJ, Patel T, Dreisbach L, McCleod M, Heim W, Hermann
RC, et al. Overall survival results from the phase III trial BMS
099: Cetuximab + taxane/carboplatin as 1st-line treatment for
advanced NSCLC. J Thorac Oncol 2008;3 (Suppl 4):S305.
23. Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M,
Ramlau R, et al. Cetuximab plus chemotherapy in patients with
advanced non-small-cell lung cancer(FLEX): an open-label
randomised phase III trial. Lancet 2009;373:1525-31. 
24. Nick T, Lynch TJ, Butts C, Rosell R, Shepherd F, Jean-Louis P, et
al. Cetuximab plus platinum-based chemotherapy as 1st-line
treatment in patients with non-small cell lung cancer (NSCLC): a
meta-analysis of randomized phase II/III trials. J Thorac Oncol
2009;4 (Suppl 1):S297. 
25. Pirker R, Szczesna A, von Pawel J, Krzakowski M, Ramlau R,
Park K, et al. FLEX: a randomized, multicenter, phase III study
of cetuximab in combination with cisplatin/vinorelbine (CV)
versus CV alone in the first-line treatment of patients with
advanced non-small cell lung cancer (NSCLC). J Clin Oncol
2008;26 (May 20 Suppl; abstr 3). 
26. Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A,
et al. Cetuximab shows activity in colorectal cancer patients with
tumors that do not express the epidermal growth factor receptor
by immunohistochemistry. J Clin Oncol 2005;23:1803-10.
27. Cappuzzo F, Finocchiaro G, Rossi E, Jänne PA, Carnaghi C,
Calandri C, et al. EGFR FISH assay predicts for response to cetu-
ximab in chemotherapy refractory colorectal cancer patients. Ann
Oncol 2008;19:717-23. 
28. Hirsch FR, Herbst RS, Olsen C, Chansky K, Crowley J, Kelly K, et
al. Increased EGFR gene copy number detected by fluorescent In
situ hybridization predicts outcome in non-small-cell lung cancer
patients treated with cetuximab and chemotherapy. J Clin Oncol
2008;26:3351-7.
29. Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison
CT,  Wu S, et al. Expression of epiregulin and amphiregulin and
K-ras mutation status predict disease control in metastatic colorec-
tal cancer patients treated with cetuximab. J Clin Oncol 2007;25:
3230-7. 
First-Line Treatment in Asian Patients with Advanced NSCLC
Yonsei Med J   http://www.eymj.org    Volume 51   Number 1   January 2010 7
Byoung Chul Cho, et al.
Yonsei Med J   http://www.eymj.org    Volume 51   Number 1   January 20108
30. Frattini M, Saletti P, Romagnani E, Martin V, Molinari F, Ghisletta
M, et al. PTEN loss of expression predicts cetuximab efficacy in
metastatic colorectal cancer patients. Br J Cancer 2007;97:1139-45.
31. Peréz-Soler R, Saltz L. Cutaneous adverse effects with HER1/
EGFR-targeted agents: is there a silver lining? J Clin Oncol 2005;
23:5235-46.
32. Gatzemeier U, Paz-Ares L, Rodrigues Pereira J, von Pawel J,
Ramlau, R, Roh JK, et al. Molecular and clinical biomarkers of
cetuximab efficacy: data from the phase III FLEX study in non-
small cell lung cancer (NSCLC). J Thorac Oncol 2009;4 (Suppl
1):S324.
